fda compounding glp-1 enforcement news november 2025 Beyond the Headlines: Warning Letters to Compounders What Patients Need to Know

For patients and clinicians, the current evidence underscores the importance of personalized medicine

BPC-157 : TB500 (Thymosin Beta 4) : BPC-157 & TB500 (Thymosin Beta 4) CERTIFICATES OF ANALYSIS 6 COAs BN-26BT11-001 Current Variant: Size: 10mg-10mg BPC-157 11.7 mg / 11.85 mg TB-500 11.54 mg / 11.44 mg BN-25BT55-004 Current Variant: Size: 5mg-5mg BPC-157 5.89 mg / 5.73 mg TB-500 5.68 mg / 5.57 mg BN-24BT55 Upcoming Variant: Size: 5mg-5mg BPC-157 5.57 mg TB-500 5.49 mg BN-25BT11-002 Previous Variant: Size: 10mg-10mg BN-25BT11-001 Previous Variant: Size: 10mg-10mg BN-24BT55-001 Previous Variant: 5 mg / 5 mg Formulation BPC-157 and TB-500 (Thymosin Beta-4) are research peptides supplied for use in controlled laboratory and analytical environments

This combination is particularly beneficial for those facing obesity or low testosterone levels

Lyophilised (freeze-dried) peptides are best kept sealed, cool and away from light, with long-term storage in a freezer to preserve stability

UK Guidance Many women with type 2 diabetes or obesity wonder whether GLP-1 receptor agonistssuch as semaglutide, liraglutide, or dulaglutideare safe whilst breastfeeding

H.SchrenkD